Target Professions: MD, Nurse, Nurse Practitioner, Pharmacist
Target Specialties: Family Medicine, Hematology, Internal Medicine, Oncology, Pharmacy
Credits Available: 3.5 AMA PRA Category 1 Credits™ for physicians; 3.5 ANCC Contact Hours for nurses and nurse practitioners, 3.5 ACPE Continuing Pharmacy Education Credits

3.5-credit-hour educational curriculum that brings together 10 groups of 10 professionally connected clinicians led by an expert (called a Group Leader) to comprehensively review key information and best practices to help clinicians formulate their own practice action plans in the care of patients with DLBCL.


CME/CE Accreditation Information

Itinerary

Part 1: Modules & Discussion

Reaching and Teaching Community-Based Clinicians to Improve Outcomes in CAR T-cell Therapy for DLBCL - Baseline Assessment

Answer the following questions to assess your knowledge on the management of refractory/relapsed DLBCL.

Module 1: What Does the Data Say About CAR T-cell Therapies for Patients with DLBCL?

In self-study Module 1 you can review the effectiveness and safety data on using CAR T-cell therapies in patients with refractory and relapsed DLBCL by looking at a patient case discussion.

Module 2: Choosing a CAR T-cell Therapy for Your Patient

In self-study Module 2 you can review new and emerging treatment options for patients with previously treated DLBCL by looking at a patient case discussion.

Live Group Discussion #1: Gap Analysis: Review of Self-Assessment Data

The purpose of this discussion is to review identified gaps in knowledge, competence, and confidence related to the care of patients with DLBCL, both through self-analysis and through review of the pre-assessment data.

Part 2: Case Studies, Live Discussion, Final Assessment, Post Group Assessment

Case Study 1 - John Z, a 69 year old male

Meet John Z, a 69 year old male presenting with a relapsed diffuse large B-cell lymphoma.

Case Study 2 - AM, a 77-year-old white female

Meet AM, a 77-year-old white female with stage 4 diffuse large B-cell lymphoma (DLBCL), concerned with treatment options and challenges to receiving treatment.

Create an Action Plan

In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with DLBCL.

Live Group Discussion #2: Case Study Analyses and Action Plan Review

The purpose of this discussion is to present the two case studies and provide an analysis of the responses. During this discussion, action plans will also be presented as we reflect on how our practice will change as a result of this CME activity.

Final Assessment - Reaching and Teaching Community-Based Clinicians to Improve Outcomes in CAR T-cell Therapy for DLBCL

Now that you have reviewed the self-study modules, answer the following questions to assess your gained knowledge on the assessment of and treatment options for refractory and relapsed DLBCL.

Interested in becoming a Group Leader?

Requirements:
Group leaders should be well versed in the diagnosis, assessment, and management of patients with DLBCL and have a working knowledge of working in collaboration with other healthcare professionals. Group leaders include clinicians involved in specialized care for patients with DLBCL, clinical research studies related to choosing appropriate therapy for relapsed or refractive disease, or associated clinical teaching. Apply Now

You cannot sign up as a Group Member because there are no groups available or because you are already signed up.

Completed Groups

Kami Maddocks, MD
MD, Professor of Clinical Internal Medicine
Completed
Pallawi Torka, MD
Completed
JW
Jason Westin, MD
Associate Professor
Completed
MS
Melody Smith, MD, MS
Assistant Professor of Medicine
Completed
Caron Jacobson, MD
Associate Professor of Medicine
Completed
Jose Galeas, MD
MD
Completed
Lynnette Henshaw, PharmD
Clinical Pharmacy Specialist - Hematology/Oncology
Completed
Akriti Jain, MD
Completed
Izidore Lossos, MD
Completed